Nanostructured delivery systems with improved leishmanicidal activity: a critical review
Natascia Bruni1, Barbara Stella2, Leonardo Giraudo1
1Candioli Pharmaceutical Institute Srl, Beinasco, Italy.
International Journal of Nanomedicine
|August 11, 2017
Summary
Nanotechnology offers a promising solution for leishmaniasis treatment by improving drug delivery. Nanosystems enhance drug bioavailability and target infected cells, overcoming current therapy limitations.
Area of Science:
- Parasitology
- Nanomedicine
- Drug Delivery
Background:
- Leishmaniasis is a widespread vector-borne zoonotic disease caused by *Leishmania* parasites, presenting diverse clinical forms.
- Current antileishmanial treatments face challenges including drug resistance, toxicity, cost, and poor efficacy against intracellular amastigotes.
- The disease affects millions globally, necessitating innovative therapeutic strategies.
Purpose of the Study:
- To review the advancements and potential of nanotechnology in improving antileishmaniasis drug delivery.
- To critically evaluate nanocarrier systems for enhanced efficacy and reduced toxicity in leishmaniasis treatment.
- To provide insights into future directions for nanomedicine in combating leishmaniasis.
Main Methods:
- Literature review of studies focusing on nanocarriers for antileishmaniasis drug delivery.
- Analysis of the mechanisms by which nanosystems improve drug bioavailability and target infected cells.
- Critical assessment of the advantages and limitations of various nanodelivery systems.
Main Results:
- Nanosystems demonstrate improved bioavailability and reduced toxicity of antileishmanial drugs.
- Intracellular delivery to mononuclear phagocyte system (MPS)-infected cells is enhanced by nanocarriers.
- Nanotechnology offers a versatile platform for developing more effective leishmaniasis therapies.
Conclusions:
- Nanotechnology presents a significant advancement in overcoming the challenges of current leishmaniasis treatments.
- Nanosystems facilitate targeted drug delivery to infected macrophages, improving therapeutic outcomes.
- Further research and development in nanomedicine are crucial for effective leishmaniasis control.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
45
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
45
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
57
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
57
01:23Modified-Release Drug Delivery Systems: Classification
69
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
69
01:20Modified-Release Drug Delivery Systems: Influencing Factors
72
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
72
01:19Modified-Release Drug Delivery Systems: Overview
53
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
53
01:27Bioavailability Enhancement: Drug Permeability Enhancement
263
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
263